The RBD region of the new coronavirus is a key antigenic site for vaccine design. However, when RBD monomer is used as the antigen, the immunogenicity will be weaker and the protein will be less stable. It is important to improve the stability of S-RBD. South China Vaccine at the Industry-University-Research Base of the State Key Laboratory of Respiratory Disease has developed the stable coronavirus recombinant protein dimer, which is more stable and immunogenic than the RBD monomer. Recently, it was patented by China National Intellectual Property Administration.

This project is a special sub-project of the Key Research Program of the Ministry of Science and Technology on new coronavirus research, funded by the New Coronavirus Research Special Project and the Joint Research Special Project of Guangzhou Institute of Respiratory Health and Harvard Medical School of Guangdong Province and Guangzhou Municipality.